Gold X2 Mining Inc. (TSXV: AUXX) (OTCQB: GSHRF) (FSE: DF8) (“Gold X2” or the “Company”) is pleased to announce a significant update ...

Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...

After 24 months, 34% of veterans who have heart and blood vessel disease and high cholesterol in a quality improvement program that included health care coaches and other resources had improved ...

Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader- ...

Explore why power projects face chronic cost and schedule overruns and how digital tools, modular construction, and real-time ...

Discover Telos Corporation's Q3 2025 earnings: record revenue growth, Xacta.ai launch, and raised outlook for 2026.

Topline results that were recently released from Sydnexis’s phase 3 Study of Atropine for the Reduction of Myopia Progression ...

-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...

Broadcast Retirement Network's Jeffrey Snyder discusses how to prevent cardiovascular disease at any age with Cone Health's ...

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine ...

Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 - - Potential NDA submission for schizophrenia indication targeted for Q2 2026 - - European ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...